Seeking Alpha

Oncothyreon initiates Phase 1 ONT-380 trial

  • Oncothyreon (ONTY +2.1%) initiates a Phase 1 trial of a ONT-380/ Herceptin combo in patients with brain metastases from HER2+ breast cancer. ONT-380 is developed in collaboration with Array BioPharma (ARRY +3.6%).
  • The objective of the trial will be to determine "the maximum-tolerated dose and recommended Phase 2 dose and schedule." (PR)
  • Relevant drugs in HER2+ breast cancer: GlaxoSmithKline's (GSK +1.6%) Tykerb, Puma Biotechnology's (PBYI +4%) neratinib.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|